Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 477

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Interstitial Lung Disease in Japanese Patients with Lung Cancer: A Cohort and Nested Case-Control Study

Kudoh, Shoji, Kato, Harubumi, Nishiwaki, Yutaka, Fukuoka, Masahiro, Nakata, Kouichiro, Ichinose, Yukito, Tsuboi, Masahiro, Yokota, Soichiro, Nakagawa, Kazuhiko, Suga, Moritaka, Japan Thoracic Radiology Group, Jiang, Haiyi, Itoh, Yohji, Armour, Alison, Watkins, Claire, Higenbottam, Tim, Nyberg, Fredrik·2008·American Journal of Respiratory and Critical Care Medicine

Abstract

RATIONALE: Interstitial lung disease (ILD) occurs in Japanese patients with non-small cell lung cancer (NSCLC) receiving gefitinib. OBJECTIVES: To elucidate risk factors for ILD in Japanese patients with NSCLC during treatment with gefitinib or chemotherapy. METHODS: In a prospective epidemiologic cohort, 3,166 Japanese patients with advanced/recurrent NSCLC were followed for 12 weeks on 250 mg gefitinib (n = 1,872 treatment periods) or chemotherapy (n = 2,551). Patients who developed acute ILD (n = 122) and randomly selected control subjects (n = 574) entered a case-control study. Adjusted incidence rate ratios were estimated from case-control data by odds ratios (ORs) with 95% confidence intervals (CIs) using logistic regression. Crude (observed) incidence rates and risks were calculated from cohort data. MEASUREMENTS AND MAIN RESULTS: The observed (unadjusted) incidence rate over 12 weeks was 2.8 (95% CI, 2.3-3.3) per 1,000 person-weeks, 4.5 (3.5-5.4) for gefitinib versus 1.7 (1.2-2.2) for chemotherapy; the corresponding observed naive cumulative incidence rates at the end of 12-week follow-up were 4.0% (3.0-5.1%) and 2.1% (1.5-2.9%), respectively. Adjusted for imbalances in risk factors between treatments, the overall OR for gefitinib versus chemotherapy was 3.2 (1.9-5.4), elevated chiefly during the first 4 weeks (3.8 [1.9-7.7]). Other ILD risk factors in both groups included the following: older age, poor World Health Organization performance status, smoking, recent NSCLC diagnosis, reduced normal lung on computed tomography scan, preexisting chronic ILD, concurrent cardiac disease. ILD-related deaths in patients with ILD were 31.6% (gefitinib) versus 27.9% (chemotherapy); adjusted OR, 1.05 (95% CI, 0.3-3.2). CONCLUSIONS: ILD was relatively common in these Japanese patients with NSCLC during therapy with gefitinib or chemotherapy, being higher in the older, smoking patient with preexisting ILD or poor performance status. The risk of developing ILD was higher with gefitinib than chemotherapy, mainly in the first 4 weeks.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1164/rccm.200710-1501oc

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 477

Metadata

Authors
Kudoh, S., Kato, H., Nishiwaki, Y., Fukuoka, M., Nakata, K., Ichinose, Y., Tsuboi, M., Yokota, S., Nakagawa, K., Suga, M., Japan Thoracic Radiology Group, Jiang, H., Itoh, Y., Armour, A., Watkins, C., Higenbottam, T., & Nyberg, F.
Venue
American Journal of Respiratory and Critical Care Medicine
Published
2008-06-15
Volume
177
Issue
12
Pages
1348-1357
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
OpenAlex
W1913616561
Cited by
477
References
24
FWCI
20.87
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Interstitial Lung Disease in Japanese Patients with Lung Cancer: A Cohort and Nested Case-Control Study. https://app.cochat.ai/papers/10.1164/rccm.200710-1501oc
The paper
Kudoh, S., Kato, H., Nishiwaki, Y., Fukuoka, M., Nakata, K., Ichinose, Y., Tsuboi, M., Yokota, S., Nakagawa, K., Suga, M., Japan Thoracic Radiology Group, Jiang, H., Itoh, Y., Armour, A., Watkins, C., Higenbottam, T., & Nyberg, F. (2008). Interstitial Lung Disease in Japanese Patients with Lung Cancer: A Cohort and Nested Case-Control Study. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.200710-1501oc

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.